Analyzing Bolt Biotherapeutics (NASDAQ:BOLT) & Sienna Biopharmaceuticals (OTCMKTS:SNNAQ)

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Risk and Volatility

Sienna Biopharmaceuticals has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sienna Biopharmaceuticals and Bolt Biotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Bolt Biotherapeutics	$7.69 million	1.44	-$63.12 million	($22.38)	-0.26

Sienna Biopharmaceuticals has higher earnings, but lower revenue than Bolt Biotherapeutics.

Profitability

This table compares Sienna Biopharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
Bolt Biotherapeutics	N/A	-94.22%	-50.56%

Institutional & Insider Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Sienna Biopharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	0.00
Bolt Biotherapeutics	1	2	2	0	2.20

Bolt Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 489.25%. Given Bolt Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Sienna Biopharmaceuticals.

Summary

Bolt Biotherapeutics beats Sienna Biopharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.